Upstream Bio Stock Performance
| UPB Stock | 31.79 0.20 0.63% |
On a scale of 0 to 100, Upstream Bio holds a performance score of 11. The entity has a beta of 0.41, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Upstream Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Upstream Bio is expected to be smaller as well. Please check Upstream Bio's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Upstream Bio's existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Upstream Bio are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Upstream Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.63 | Five Day Return 2.35 | Year To Date Return 17.44 | Ten Year Return 44.5 | All Time Return 44.5 |
1 | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 11/05/2025 |
2 | Upstream Bio to Participate in Upcoming December Investor Conferences | 11/25/2025 |
3 | Upstream Bio Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study - Seeking Alpha | 12/05/2025 |
4 | Norges Bank Acquires New Position in Upstream Bio, Inc. UPB | 12/10/2025 |
5 | Upstream Bio Stock Price Up 6.9 percent Time to Buy | 12/16/2025 |
6 | Upstream Bio Stock Rating Upgraded by Mizuho - MarketBeat | 12/19/2025 |
7 | Upstream Bio Stock Price Up 4.8 percent - Should You Buy - MarketBeat | 12/24/2025 |
8 | Acquisition by Sutherland Everett Rand of 75000 shares of Upstream Bio subject to Rule 16b-3 | 01/02/2026 |
9 | Acquisition by Sutherland Everett Rand of 225000 shares of Upstream Bio at 27.07 subject to Rule 16b-3 | 01/06/2026 |
10 | Upstream Bio Fully Priced After Recent Rally - Seeking Alpha | 01/08/2026 |
11 | Upstream Bio Reaches New 1-Year High Should You Buy | 01/14/2026 |
12 | J.P. Morgan Maintains UpStream Bio With Buy Rating, Announces Target Price 35 - | 01/20/2026 |
| Begin Period Cash Flow | 25.8 M | |
| Total Cashflows From Investing Activities | -59.5 M |
Upstream Bio Relative Risk vs. Return Landscape
If you would invest 2,358 in Upstream Bio on October 25, 2025 and sell it today you would earn a total of 821.00 from holding Upstream Bio or generate 34.82% return on investment over 90 days. Upstream Bio is generating 0.5837% of daily returns assuming volatility of 4.147% on return distribution over 90 days investment horizon. In other words, 37% of stocks are less volatile than Upstream, and above 89% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Upstream Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Upstream Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Upstream Bio, and traders can use it to determine the average amount a Upstream Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Upstream Bio is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Upstream Bio by adding it to a well-diversified portfolio.
Upstream Bio Fundamentals Growth
Upstream Stock prices reflect investors' perceptions of the future prospects and financial health of Upstream Bio, and Upstream Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Upstream Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (55.39) % | ||||
| Current Valuation | 1.34 B | ||||
| Shares Outstanding | 54.04 M | ||||
| Price To Book | 4.51 X | ||||
| Price To Sales | 609.89 X | ||||
| Revenue | 2.37 M | ||||
| Gross Profit | 2.8 M | ||||
| EBITDA | (77.67 M) | ||||
| Net Income | (62.81 M) | ||||
| Total Debt | 1.83 M | ||||
| Book Value Per Share | 7.01 X | ||||
| Cash Flow From Operations | (59.17 M) | ||||
| Earnings Per Share | (6.40) X | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 481.72 M | ||||
| Retained Earnings | (190.78 M) | ||||
| Working Capital | 468.42 M | ||||
About Upstream Bio Performance
By analyzing Upstream Bio's fundamental ratios, stakeholders can gain valuable insights into Upstream Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Upstream Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Upstream Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.12) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.13) | (0.15) |
Things to note about Upstream Bio performance evaluation
Checking the ongoing alerts about Upstream Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Upstream Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Upstream Bio appears to be risky and price may revert if volatility continues | |
| Upstream Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 2.37 M. Reported Net Loss for the year was (62.81 M) with profit before taxes, overhead, and interest of 2.8 M. | |
| Upstream Bio generates negative cash flow from operations | |
| Over 93.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: J.P. Morgan Maintains UpStream Bio With Buy Rating, Announces Target Price 35 - |
- Analyzing Upstream Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Upstream Bio's stock is overvalued or undervalued compared to its peers.
- Examining Upstream Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Upstream Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Upstream Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Upstream Bio's stock. These opinions can provide insight into Upstream Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Upstream Stock analysis
When running Upstream Bio's price analysis, check to measure Upstream Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio is operating at the current time. Most of Upstream Bio's value examination focuses on studying past and present price action to predict the probability of Upstream Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio's price. Additionally, you may evaluate how the addition of Upstream Bio to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges |